Documentation of Consciousness with Olanzapine Administration
Document baseline level of consciousness using a standardized agitation scale before administering olanzapine, then reassess at 15-30 minutes, 2 hours, and 4 hours post-injection, with particular attention to orthostatic vital signs and respiratory status before any subsequent doses.
Pre-Administration Assessment
Before giving olanzapine, document the following:
- Baseline agitation level using a validated scale such as the PANSS-EC (Positive and Negative Syndrome Scale-Excited Component), BARS (Behavioral Activity Rating Scale), or Clinical Global Impressions Scale 1
- Baseline vital signs including blood pressure (both supine and standing if feasible), heart rate, respiratory rate, and oxygen saturation 2
- Current level of consciousness using descriptive terms (alert, drowsy, obtunded) or Glasgow Coma Scale
- Baseline orthostatic blood pressure is particularly important, as maximal dosing may cause substantial orthostatic hypotension 2
Post-Administration Monitoring Schedule
Immediate Monitoring (First 30 Minutes)
- Assess consciousness level at 15-30 minutes post-injection, as this is when initial therapeutic effects appear 1
- Monitor for hypoxia (oxygen saturation <92%), which occurred in 10.4% of patients in one large ED cohort 3
- Watch for excessive sedation, as 21% of patients receiving IM haloperidol plus lorazepam could not be evaluated at 30 minutes due to sleep 1
Subsequent Dose Considerations (2-4 Hours)
Before administering any additional doses, mandatory assessment includes:
- Orthostatic vital signs - measure blood pressure supine and standing to detect clinically significant postural changes in systolic blood pressure 2
- Level of consciousness - do not give additional doses to patients with significant postural hypotension 2
- Respiratory status - major respiratory complications requiring airway intervention occurred in 2.1% of patients receiving IV olanzapine 3
The FDA label explicitly states: "patients requiring subsequent intramuscular injections be assessed for orthostatic hypotension prior to the administration of any subsequent doses" 2
Specific Documentation Elements
Consciousness Parameters to Record
- Alertness level - fully alert, drowsy but arousable, difficult to arouse, unarousable
- Response to verbal stimuli and physical stimuli if needed
- Pupil size and reactivity - note that pinpoint pupils may indicate overdose 4
- Respiratory rate and effort - document any signs of respiratory distress 4
- Oxygen saturation on room air or supplemental oxygen 3
Timing of Assessments
- Baseline (pre-administration)
- 15-30 minutes post-dose (initial effect assessment) 1
- 2 hours post-dose (before considering second dose) 2
- 4 hours post-dose (before considering third dose) 2
- 24 hours for overall response assessment 1
Critical Safety Considerations
Maximum Dosing Limits
- Total daily dose should not exceed 30 mg 2
- Minimum interval between doses: 2 hours after first dose, 4 hours after second dose 2
- Three doses of 10 mg administered 2-4 hours apart may cause substantial orthostatic hypotension 2
High-Risk Situations Requiring Enhanced Monitoring
- Concurrent benzodiazepine use - lorazepam should not be used to reconstitute IM olanzapine 2
- Alcohol or drug intoxication - 16.5% of patients in one ED cohort were ethanol-positive 3
- Elderly or debilitated patients - use lower doses (2.5-5 mg) and monitor more frequently 2
Rare but Serious Complications to Document
- Neuroleptic malignant syndrome - decreased consciousness, muscle rigidity, fever, diaphoresis 5
- Acute muscle toxicity - check CPK levels if clinically indicated 6
- Post-injection syndrome (with depot formulations) - acute intoxication with loss of consciousness, requiring 3-hour observation 4
Documentation Template
A practical documentation format should include:
Pre-dose: Time, agitation scale score, vital signs (BP supine/standing, HR, RR, SpO2), consciousness level, dose administered, route
Post-dose intervals (15-30 min, 2h, 4h): Time, consciousness level, vital signs including orthostatic BP, respiratory status, agitation scale score, need for additional interventions
This structured approach ensures patient safety while meeting the FDA-mandated monitoring requirements for olanzapine administration 2.